StockWatch
·
HomeLiveReports

Excelsoft Technologies Ltd Q1 FY27 Results

EXCELSOFTQ1 FY27 Results
Result:Weak· Market: Flat

Outlook: Optimistic · Guidance: Cut

MetricValue (₹ Cr)vs Q4 FY26
Revenue80.261.1%
Total Income86.100.7%
Expenditure74.2717.3%
PBT11.8347.9%
Net Profit9.2344.4%
OPM16.24%13.20pp
NPM10.72%8.43pp
EPS0.8046.7%
View full financials

No YoY comps disclosed to judge revenue/margin trajectory, and core operating profit (Revenue−Expenses ≈ ₹6cr) leans heavily on Other Income (₹5.8cr, ~49% of PBT) for the ₹9.2cr NetProfit, so this reads as in-line rather than a standout IT quarter.

EXCELSOFT TECHNOLOGIES · Q1 FY-2027 · THE VERDICT

Strong Growth, Dented Margins: How Excelsoft's FY27 Outlook Broke the Market's Patience

Q1 revenue jumped 44%, PAT surged 57%, yet management cut FY27 EBITDA guidance from 30-31% to 24-25%. The market voted with its feet: an 11% sell-off says growth without margin recovery isn't enough.

19 Aug 2026 · 6 min read
Reported PAT

₹9.2 Cr

+57% YoY

EBITDA margin

16.2%

-178 bps YoY

FY27 margin guidance

24-25%

vs prior 30-31%

AQA Q1 revenue

₹2.5 Cr

₹12-15 Cr FY27 target

On the revenue screen, Excelsoft nailed it: ₹80.3 crore in Q1 is a clean 44% year-on-year jump, with PAT up 57% to ₹9.2 crore. But the street's 11% sell-off by day 5 was not about missing growth. It was about what management just telegraphed on margins. The company cut its FY27 EBITDA margin guidance from 30-31% (the prior call's assurance) all the way down to 24-25%. That's 600 basis points of retrenchment, and it says: 'the growth isn't coming with the profitability we once promised.'

Where the margin went — and why it's not coming back soon

Q1's EBITDA margin of 16.2% is down 178 basis points from 18.0% the year before. Management cited ₹1.46 crore in one-time costs for the US nearshore team build-out, which sounds cushiony—but it only explains about 40 basis points of the decline. The other 138 basis points are structural: sales team expansion, nearshore capacity building, and AI-native product investments that won't fully unwind. Management's honest trade-off: 'We prefer 30%+ revenue growth at 25% margins over slower growth at higher margins.' In other words, they're betting growth will eventually drive fixed-cost leverage. The question is whether that bet plays out before the market's patience runs out.

Management's core claims: what holds up and what doesn't

ETS grew 177% YoY, a primary growth engine

Confirmed: ETS at ₹50.9 Cr (+177% YoY), 63.4% of revenue, nearshore ₹10 Cr embedded within

Supported

Nearshore at 26% gross margin with ₹40 Cr FY27 visibility

Q1 nearshore: ₹10 Cr revenue, 26% margin confirmed. ₹40 Cr annual order book stated but not yet fully secured

Supported (with caveat)

EBITDA margins broadly stable excluding one-time costs

16.24% Q1 vs 18.02% prior year; one-time costs only ~40 bps add-back, implying 138 bps structural decline

Overstated

Return to 30-31% EBITDA margins (prior call)

Now guiding 24-25% for FY27 amid ongoing sales/nearshore/AI investments. No recovery timeline committed

Contradicted

AQA engagement generating revenue with scale-up ahead

₹2.5 Cr booked Q1; ₹12-15 Cr expected FY27; USD 17 million over 4 years confirmed

Supported

What changed on this call versus prior guidance

Three big shifts landed this quarter. First, margin guidance retreated: last call, management signaled a return to 30-31% EBITDA margins as one-time US nearshore costs wound down. Now: 24-25% for FY27, with no timeline to recover. The gap is real and structural—sales expansion, nearshore capacity, and AI product development are not temporary. Second, nearshore pivoted from pilot to production: what was a small-scale initiative last quarter is now material at ₹10 crore in Q1 revenue (26% margin) with a ₹40 crore annual order book in flight. The mechanism is de-risked, but execution is not—margins need to ramp to 35-40% for the expansion story to work. Third, AQA escalated: previously an 'engagement signed, work in progress' milestone, now ₹2.5 crore booked in Q1, ₹12-15 crore expected FY27, and a credible USD 17 million four-year visibility. This moves from promise to delivery, and will make AQA the company's second-largest account.

The bull-bear ledger

  • 44% revenue growth validates the investment thesis

  • AQA is real revenue, not vaporware; USD 17M over 4 years anchors the upside

  • Nearshore mechanism tangible: ₹10 Cr Q1, 26% margin, ₹40 Cr order book in hand

  • ₹400 crore in cash + FDs provides dry powder for M&A and capex

  • EBITDA margin guidance cut 600 bps despite strong topline growth

  • Structural investments (sales, nearshore, AI) have no clear recovery timeline

  • Customer concentration 70% top-5, 83% top-10; AQA ramp could amplify single-account risk

  • Nearshore margin expansion 26% → 35-40% is aspirational, not guaranteed

  • FY27 guidance implies EBITDA margin of ~24-25% even if revenue hits top-end ₹360 Cr

Ranked risks—what should concern a holder most

Severity and consequence of key execution risks

Nearshore margin expansion stalls

High

26% gross margin is competitive with offshore. If utilization doesn't ramp or talent attrition occurs, the ₹40 Cr order book erodes into commodity pricing. Would drag FY27 EBITDA below 24-25% guidance.

AQA deployment delayed or scaled down

High

₹12-15 Cr FY27 target now baked into the growth narrative. A 25% miss = ₹3+ Cr revenue gap, ~5-7% of FY27 guidance. Would force another guidance cut.

Customer concentration crystallizes into churn risk

Medium

Top 5 customers = 70% of revenue. AQA becoming 2nd largest account could amplify risk. Loss of one strategic account in top-5 = 10-15% revenue hit.

Margin recovery timeline extends beyond FY28

Medium

If AI product commercialization lags, nearshore utilization underwhelms, or sales spend doesn't convert to new logos, 25% EBITDA margins could become the new baseline, not a trough.

M&A targets blow up in negotiation

Low

3 targets in pipeline (1 US, 2 India), 2 with non-binding offers. If valuations spike or synergies don't materialize, inorganic growth target (30% of next 5 years) gets deferred.

How the street is positioned — and why it matters

The market's initial reaction was blunt: -7.14% on day 1, widening to -11.58% by day 5. This is not a pop-and-fade—it's a consistent repricing. The stock closed the pre-result day at ₹83.65; it's now at ₹72.59, down 13% in absolute terms since the announcement. Contextually, the stock is trading 49% below its all-time high of ₹142.59, and it's sitting below all key moving averages (SMA20 ₹77.44, SMA50 ₹78.19). The RSI of 38.6 suggests oversold territory, but not yet capitulation.

Institutional flows are negative. FII ownership fell from 1.37% in Q4 to 1.12% in Q1 (a 25-basis-point exit). DII stepped back from 4.05% to 3.10% (95 basis points). Both the foreign and domestic smart money are trimming, not adding—a signal that the growth story alone isn't compelling without margin visibility. There were no significant insider trades or block deals flagged; the sell-off is broad-based institutional lightening, not panic selling by promoters.

The thesis the market was pricing before the result: high-growth, margin-accretive EdTech play returning to 30%+ EBITDA margins. The thesis now: high-growth, margin-trapped in the mid-20s, with execution risk on nearshore and AQA ramps. The 11% repricing is the market saying, 'That trade doesn't work unless margins inflect visibly in Q2 or the full-year guides beat.'

What to watch next

Three concrete metrics that will validate or invalidate the margin story

  • 1 · Q2 EBITDA margin and nearshore utilization

    Can the company hold 24-25% EBITDA margin without another one-time cost cushion? More importantly, does nearshore margin show progress toward 30%+ gross margin, or does it stay flat at 26%? This is the leading indicator of whether the ₹40 Cr order book is accretive or dilutive.

  • 2 · AQA full deployment phases and contribution

    Is the ₹12-15 Cr FY27 guidance tracking? AQA is moving from pilot to phased full deployment. Each deployment phase is a moment of customer validation. If phases slip or the ramp is slower than ₹2.5 Cr/quarter, the ₹12-15 Cr target will be missed, and management will have to cut FY27 guidance again.

  • 3 · New logo acquisition and customer concentration

    Management says they're balancing the nearshore/AQA ramps with new logo acquisition. Do wallet share and new customer wins show up in the next two quarters, or does concentration stay at 70% top-5? If concentration widens as AQA scales, the stock will reprice as a single-account risk.

  • 4 · NTA government exam opportunity and M&A progress

    The engagement with the government task force on competitive exams could materialize into a large pilot. Similarly, are the 3 M&A targets closing in Q2-Q3, or is deal complexity / valuation disputes delaying them further? Either outcome will shift the growth mix and capital allocation story.

Excelsoft is executing on growth—44% revenue expansion, AQA at scale, nearshore traction are all real. But the company has traded profitability for speed, and the market is right to withhold re-rating until margin recovery is credible and visible. The stock's 49% drawdown from its all-time high is material, and institutional selling post-result signals skepticism on the growth-without-margin narrative.

This quarter was about validation of the growth thesis; the next quarter is about whether the margin thesis holds. Until margins stabilize at 27-30% or the company commits to a recovery timeline, the stock will stay defensive. The number to track: EBITDA margin in Q2. If it holds 24-25% with visible nearshore progress, bulls have a case. If it dips below 24%, expect another 8-10% sell-off and a fresh round of guidance cuts. Growth is proven; margins are the test.

Informational and educational content only. Not investment advice.